Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s ...

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and ...

The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a ...

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a ...